In silico identification of egfr-t790m inhibitors with novel scaffolds: Start with extraction of common features

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 789-839

  Xiang, Mingli ^a   Lei, Kai ^a   Fan, Wenjie ^a   Lin, Yuchun ^b   He, Gu ^a   Yang, Mingli ^c   Chen, Lijuan ^a   Mo, Yirong ^d  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SICHUAN UNIVERSITY   (China)

^d WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Drug resistant; Mutant egfr; Nci database; Pharmacophore modeling; Quantum chemical calculation; Virtual screening

Indexed keywords

ANTINEOPLASTIC AGENT; MOLECULAR SCAFFOLD; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; T 001; T 009; T 013; T 016; T 018; T 019; T 106; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR INHIBITOR; WZ 3146; WZ 4002; WZ 8040;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; IC 50; MOLECULAR LIBRARY; PHARMACOPHORE; PHARMACOPHORE MODELING; VALIDATION STUDY;

DRUG RESISTANT; MUTANT EGFR; NCI DATABASE; PHARMACOPHORE MODELING; QUANTUM CHEMICAL CALCULATION; VIRTUAL SCREENING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL MOLECULE LIBRARIES;

EID: 84881579575     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41305     Document Type: Article

References (61)

1. Shimizu N, Behzadian MA, Shimizu Y. Genetics of cell surface receptors for bioactive polypeptides: binding of epidermal growth factor is associated with the presence of human chromosome 7 in human-mouse cell hybrids. Proc Natl Acad Sci U S A. 1980;77(6):3600-3604.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-225.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
4. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462(7276):1070-1074.
5. Carmi C, Cavazzoni A, Vezzosi S, et al. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem. 2010;53(5):2038-2050.
6. Bai F, Liu H, Tong L, et al. Discovery of novel selective inhibitors for EGFR-T790M/L858R. Bioorg Med Chem Lett. 2012;22(3): 1365-1370.
7. Li S, Guo C, Sun X, et al. Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. Eur J Med Chem. 2012;49: 271-278.
8. Sato T, Watanabe H, Tsuganezawa K, et al. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures. Bioorg Med Chem. 2012;20(12):3756-3767.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183-232.
10. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319(1):1-11.
11. Gazdar AF. Activating and resistance mutations of EGFR in non-smallcell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28 Suppl 1:S24-S31.
12. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-1134.
13. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009;77(6):400-410.
14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354.
15. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. 2010;69(1): 1-12.
16. Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007;12(3):325-330.
17. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105(6):2070-2075.
18. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218(3):460-466.
19. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17(5):589-595.
20. Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/ HER2 inhibitor BIBW 2992. Target Oncol. 2010;5(4):245-255.
21. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007;14(3):295-304.
22. Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J. 2010;277(2):309-315.
23. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med. 2008;358(11):1160-1174.
24. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005;65(16):7096-7101.
25. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e313.
26. Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol. 2008;3(6 Suppl 2):S146-S149.
27. Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins. 2006;65(2):331-346.
28. Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim). 2008;341(8):465-477.
29. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-4711.
30. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924-11932.
31. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102(21):7665-7670.
32. Godin-Heymann N, Ulkus L, Brannigan BW, et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008;7(4): 874-879.
33. Blair JA, Rauh D, Kung C, et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007;3(4):229-238.
34. Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005;48(4):1107-1131.
35. Wissner A, Overbeek E, Reich MF, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem. 2003;46(1):49-63.
36. Wissner A, Brawner Floyd MB, Rabindran SK, et al. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg Med Chem Lett. 2002;12(20):2893-2897.
37. Tsou HR, Mamuya N, Johnson BD, et al, 6-Substituted-4 (3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem. 2001;44(17):2719-2734.
38. Marvin, http://www.chemaxon.com [computer program]. Version 5.6.0.1: ChemAxon Ltd; 2011.
39. Halgren TA., Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17(5-6):490-519.
40. Gaussian 03 [computer program]. Version Revision C.02 ed. Wallingford CT: Gaussian, Inc; 2004.
41. Yang W, Mortier WJ. The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines. J Am Chem Soc. 1986;108(19):5708-5711.
42. Boström J. Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools. J Comput Aided Mol Des. 2001;15(12):1137-1152.
43. Discovery Studio Modeling Environment [computer program]. Version Release 3.1. San Diego: Accelrys Software Inc; 2012.
44. Michalczyk A, Klüter S, Rode HB, et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem. 2008;16(7):3482-3488.
45. FRED program. http://www.eyesopen.com [computer program]. Version Version 2.2.5: OpenEye Scientific Software Inc.,Santa Fe, NM, USA; 2012.
46. Nicholls A, Grant JA, Brown FK. Gaussian docking functions. Biopolymers. 2003;68(1):76-90.
47. Verkhivker GM, Bouzida D, Gehlhaar DK, et al. Deciphering common failures in molecular docking of ligand-protein complexes. J Comput Aided Mol Des. 2000;14(8):731-751.
48. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des. 1997;11(5):425-445.
49. Stahl M, Rarey M. Detailed analysis of scoring functions for virtual screening. J Med Chem. 2001;44(7):1035-1042.
50. Grant JA, Pickup BT, Nicholls A. A smooth permittivity function for Poisson-Boltzmann solvation methods. J Comput Chem. 2001;22(6):608-640.
51. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther. 1999;82(2-3):195-206.
52. Cavasotto CN, Ortiz MA, Abagyan RA, Piedrafita FJ. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Bioorg Med Chem Lett. 2006;16(7):1969-1974.
53. Rode HB, Sos ML, Grütter C, Heynck S, Simard JR, Rauh D. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino) isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorg Med Chem. 2011;19(1):429-439.
54. Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ. Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem. 2004;11(1):71-90.
55. Güner OF. History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem. 2002;2(12): 1321-1332.
56. Xiang M, Cao Y, Fan W, Chen L, Mo Y. Computer-aided drug design: lead discovery and optimization. Comb Chem High Throughput Screen. 2012;15(4):328-337.
57. Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl. 2003;42(24):2718-2736.
58. Tuccinardi T. Docking-based virtual screening: recent developments. Comb Chem High Throughput Screen. 2009;12(3):303-314.
59. Plewczynski D, Łazniewski M, von Grotthuss M, Rychlewski L, Ginalski K. VoteDock: consensus docking method for prediction of protein-ligand interactions. J Comput Chem. 2011;32(4):568-581.
60. Schapira M, Abagyan R, Totrov M. Nuclear hormone receptor targeted virtual screening. J Med Chem. 2003;46(14):3045-3059.
61. Ravindranathan KP, Mandiyan V, Ekkati AR, Bae JH, Schlessinger J, Jorgensen WL. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J Med Chem. 2010;53(4):1662-1672.